search
Back to results

Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans

Primary Purpose

Type 2 Diabetes

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Glycemic clamping
Sponsored by
Medical College of Wisconsin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 2 Diabetes focused on measuring Endothelial Function, Hypoglycemia, Mitochondria

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

- Type 2 Diabetes Inclusion Criteria

  1. Adult age 21 or older
  2. If on 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase reductase therapy, must be on a stable dose for at least 6 weeks prior to enrollment
  3. Diagnosis of type 2 diabetes by a physician as defined by the American Diabetes Association standard criteria: 1) Fasting Plasma glucose at or above 126 mg/dL 2) a two-hour value in an oral glucose tolerance test at or above 200 mg/dL, or 3) a random plasma glucose concentration 200 mg/dL in the presence of symptoms, or 4) glycosylated hemoglobin greater than or equal to 6.5%.

Score of < 4 using the Gold method for assessing hypoglycemia awareness

Inclusion Criteria for Healthy subjects

  1. Adult age 21 or older
  2. No evidence of metabolic syndrome or diabetes, hypertension (BP≥140/90), or high cholesterol (LDL≥160) at the time of screen.

Exclusion Criteria:

  1. History of stroke, peripheral arterial disease, or coronary artery disease (as defined by the presence of at least one coronary stenosis ≥ 40% on angiography or by confirmed history of myocardial infarction by standard criteria)
  2. Evidence of other evident major illness including chronic renal insufficiency(plasma creatinine > 1.4 for women or 1.5 for men), liver disease (aspartate aminotransferase or alanine aminotransferase greater than 2.5 x normal), and cancer currently undergoing therapy or had therapy for cancer within 1 year of enrollment.
  3. Pregnancy as determine by urinary pregnancy test
  4. Subjects on warfarin, oral anti-thrombin inhibitors, or thienopyridines
  5. Subjects who have had changes to dosing of thiazolidinedione, dipeptidyl peptidase-4 (DPP-4) inhibitor, or metformin therapy within 6 weeks of enrollment.
  6. Failed Allen's test in both arms - unable to safely place an arterial line
  7. Glucose reading of < 50 mg/dL and/or episodes of symptomatic hypoglycemia requiring the assistance of another person for recovery in the 2 years prior to enrollment.
  8. History of hypoglycemic convulsions
  9. Current fluoxetine therapy (known to interfere with neuroendocrine response to hypoglycemia)
  10. Glycosylated hemoglobin over 8.5%
  11. On aldosterone antagonist therapy at the time of enrollment
  12. On insulin therapy at the time of screening.
  13. History of allergy to local anesthetic injection like lidocaine.
  14. Age below 21.

Exclusion Criteria for Healthy Subjects:

  1. Meet any of the exclusion criteria for diabetic or metabolic syndrome group Meet criteria for type 2 diabetes or metabolic syndrome
  2. On medication for cholesterol or blood pressure.
  3. History of allergy to local anesthetic injection like lidocaine.

Sites / Locations

  • Medical College of Wisconsin

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Hypoglycemia First

Euglycemia First

Arm Description

Individuals will undergo a hyperinsulinemic hypoglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.

Individuals will undergo a hyperinsulinemic euglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.

Outcomes

Primary Outcome Measures

Flow induced Dilation of the Brachial Artery (FMD%)

Secondary Outcome Measures

Measurement of total and phosphorylated endothelium-derived NO synthase expression in radial artery endothelial cells.
Measurement of mitochondrial membrane potential
Performed on captured radial artery endothelial cells.
Mitochondrial superoxide production
From capture radial artery endothelial cells.

Full Information

First Posted
August 6, 2012
Last Updated
August 10, 2017
Sponsor
Medical College of Wisconsin
search

1. Study Identification

Unique Protocol Identification Number
NCT01660009
Brief Title
Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans
Official Title
Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Terminated
Why Stopped
Insufficient Funding
Study Start Date
June 2012 (undefined)
Primary Completion Date
June 2017 (Actual)
Study Completion Date
June 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical College of Wisconsin

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Prior work suggests exposure to low glucose levels (hypoglycemia) is associated with increased cardiovascular risk. However, whether there is a causal relationship between cardiovascular events and hypoglycemia remains unclear with conflicting data in the literature. In this study, we plan to study whether acute exposure of patients to clinically relevant (50-60 milligrams/deciliter) levels of hypoglycemia induces or worsens blood vessel endothelial dysfunction- a key 1st step in the development of heart attacks and strokes. This will be determined in humans both with and with type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Endothelial Function, Hypoglycemia, Mitochondria

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hypoglycemia First
Arm Type
Experimental
Arm Description
Individuals will undergo a hyperinsulinemic hypoglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
Arm Title
Euglycemia First
Arm Type
Experimental
Arm Description
Individuals will undergo a hyperinsulinemic euglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
Intervention Type
Other
Intervention Name(s)
Glycemic clamping
Intervention Description
During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
Primary Outcome Measure Information:
Title
Flow induced Dilation of the Brachial Artery (FMD%)
Time Frame
1 hour
Secondary Outcome Measure Information:
Title
Measurement of total and phosphorylated endothelium-derived NO synthase expression in radial artery endothelial cells.
Time Frame
1 hour
Title
Measurement of mitochondrial membrane potential
Description
Performed on captured radial artery endothelial cells.
Time Frame
1 hour
Title
Mitochondrial superoxide production
Description
From capture radial artery endothelial cells.
Time Frame
1 hour

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: - Type 2 Diabetes Inclusion Criteria Adult age 21 or older If on 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase reductase therapy, must be on a stable dose for at least 6 weeks prior to enrollment Diagnosis of type 2 diabetes by a physician as defined by the American Diabetes Association standard criteria: 1) Fasting Plasma glucose at or above 126 mg/dL 2) a two-hour value in an oral glucose tolerance test at or above 200 mg/dL, or 3) a random plasma glucose concentration 200 mg/dL in the presence of symptoms, or 4) glycosylated hemoglobin greater than or equal to 6.5%. Score of < 4 using the Gold method for assessing hypoglycemia awareness Inclusion Criteria for Healthy subjects Adult age 21 or older No evidence of metabolic syndrome or diabetes, hypertension (BP≥140/90), or high cholesterol (LDL≥160) at the time of screen. Exclusion Criteria: History of stroke, peripheral arterial disease, or coronary artery disease (as defined by the presence of at least one coronary stenosis ≥ 40% on angiography or by confirmed history of myocardial infarction by standard criteria) Evidence of other evident major illness including chronic renal insufficiency(plasma creatinine > 1.4 for women or 1.5 for men), liver disease (aspartate aminotransferase or alanine aminotransferase greater than 2.5 x normal), and cancer currently undergoing therapy or had therapy for cancer within 1 year of enrollment. Pregnancy as determine by urinary pregnancy test Subjects on warfarin, oral anti-thrombin inhibitors, or thienopyridines Subjects who have had changes to dosing of thiazolidinedione, dipeptidyl peptidase-4 (DPP-4) inhibitor, or metformin therapy within 6 weeks of enrollment. Failed Allen's test in both arms - unable to safely place an arterial line Glucose reading of < 50 mg/dL and/or episodes of symptomatic hypoglycemia requiring the assistance of another person for recovery in the 2 years prior to enrollment. History of hypoglycemic convulsions Current fluoxetine therapy (known to interfere with neuroendocrine response to hypoglycemia) Glycosylated hemoglobin over 8.5% On aldosterone antagonist therapy at the time of enrollment On insulin therapy at the time of screening. History of allergy to local anesthetic injection like lidocaine. Age below 21. Exclusion Criteria for Healthy Subjects: Meet any of the exclusion criteria for diabetic or metabolic syndrome group Meet criteria for type 2 diabetes or metabolic syndrome On medication for cholesterol or blood pressure. History of allergy to local anesthetic injection like lidocaine.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael E Widlansky, MD, MPH
Organizational Affiliation
Medical College of Wisconsin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans

We'll reach out to this number within 24 hrs